Dr. Peter Coffey from University College London shares his work with the London Project to Cure Blindness, which resulted in the first clinical stem cell trial to treat blindness, and discusses cell quality requirements for clinical trials. This presentation and the following Q&A session were moderated by Dr. Christine Mummery from the Leiden University Medical Center.
This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.
Note: Some original data from this presentation has been omitted to abide by copyright rules.
To view the webinar, please complete the form, or sign in to your account.